

# India Glaucoma Outcomes and Treatment Trial

<b>Submission date</b> 11/10/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 30/03/2006	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input checked="" type="checkbox"/> Results
<b>Last Edited</b> 11/01/2021	<b>Condition category</b> Eye Diseases	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Nathan Congdon

**Contact details**  
Wilmer 120  
600 N. Wolfe Street  
Baltimore  
United States of America  
21287  
-  
ncongdon@jhmi.edu

## Additional identifiers

**EudraCT/CTIS number**

**IRAS number**

**ClinicalTrials.gov number**

**Secondary identifying numbers**  
N/A

## Study information

**Scientific Title**

# India Glaucoma Outcomes and Treatment Trial

## Acronym

INGOTT

## Study objectives

Surgery will be more effective than medicines in controlling glaucoma in India

## Ethics approval required

Old ethics approval format

## Ethics approval(s)

Approved by the Internal Review Boards at the Johns Hopkins University, Baltimore, USA and the Aravind Eye Hospital in India

## Study design

Randomised controlled trial

## Primary study design

Interventional

## Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

## Study type(s)

Treatment

## Participant information sheet

## Health condition(s) or problem(s) studied

Glaucoma

## Interventions

Medicine (timolol, latanaprost and brimonidine) versus surgery

## Intervention Type

Procedure/Surgery

## Primary outcome measure

1. Intraocular pressure
2. Visual acuity
3. Quality of life

## Secondary outcome measures

Cataract grade

## Overall study start date

01/01/2003

**Completion date**

01/01/2007

## Eligibility

**Key inclusion criteria**

Glaucoma patients over the age of 30 years in India

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

700

**Total final enrolment**

398

**Key exclusion criteria**

1. Previous surgery
2. Intraocular pressure (IOP) >35

**Date of first enrolment**

01/01/2003

**Date of final enrolment**

01/01/2007

## Locations

**Countries of recruitment**

India

United States of America

**Study participating centre**

Wilmer 120

Baltimore

United States of America

21287

# Sponsor information

## Organisation

Pfizer Inc. (USA)

## Sponsor details

Corporate Headquarters  
New York  
United States of America  
20001

## Sponsor type

Industry

## ROR

<https://ror.org/01xdqrp08>

# Funder(s)

## Funder type

Industry

## Funder Name

Pfizer Inc.

# Results and Publications

## Publication and dissemination plan

Not provided at time of registration

## Intention to publish date

## Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/06/2012	11/01/2021	Yes	No